Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Operating Expenses: 2017-2024

Historic Operating Expenses for Kiniksa Pharmaceuticals International (KNSA) over the last 8 years, with Dec 2024 value amounting to $468.9 million.

  • Kiniksa Pharmaceuticals International's Operating Expenses rose 28.69% to $156.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $559.8 million, marking a year-over-year increase of 36.43%. This contributed to the annual value of $468.9 million for FY2024, which is 58.69% up from last year.
  • As of FY2024, Kiniksa Pharmaceuticals International's Operating Expenses stood at $468.9 million, which was up 58.69% from $295.5 million recorded in FY2023.
  • Kiniksa Pharmaceuticals International's Operating Expenses' 5-year high stood at $468.9 million during FY2024, with a 5-year trough of $157.4 million in FY2020.
  • Over the past 3 years, Kiniksa Pharmaceuticals International's median Operating Expenses value was $295.5 million (recorded in 2023), while the average stood at $324.9 million.
  • Its Operating Expenses has fluctuated over the past 5 years, first dropped by 7.41% in 2020, then soared by 58.69% in 2024.
  • Kiniksa Pharmaceuticals International's Operating Expenses (Yearly) stood at $157.4 million in 2020, then increased by 24.03% to $195.2 million in 2021, then rose by 7.80% to $210.4 million in 2022, then soared by 40.42% to $295.5 million in 2023, then soared by 58.69% to $468.9 million in 2024.